Theravance Biopharma

NYSE/NASDAQ:TBPHPharma

San Francisco, California, United States · Est. 2014

Theravance Biopharma is a biopharmaceutical company focused on developing and commercializing innovative medicines in respiratory and oncology therapeutic areas.

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

1 drugs in development

Phase 31

By Therapeutic Area

top 1

Neurology

1100%

R&D Momentum

12/100

Pipeline Velocity

0/100

Trial Completion Rate

87/100

Pipeline Concentration

100/100

Pipeline Freshness

70/100

Activity

Key Events

Mar 19, 2026EX-99.1Theravance Biopharma, Inc. (TBPH) (CIK 0001583107)

Jun 27, 2023TrialPhase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy

Jan 7, 2022TrialPhase 4 COPD and Suboptimal Inspiratory Flow Rate

Oct 13, 2021TrialTD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental Oxygenation

May 4, 2021TrialComparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID-19

Jan 18, 2021TrialThorough QT Study to Evaluate Ampreloxetine in Healthy Subjects

Oct 16, 2020TrialSingle Dose Bioavailability and Ethnobridging PK Study in Healthy Subjects

Oct 15, 2020TrialTD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis

4 more events

Jul 23, 2020TrialTD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study

Jun 24, 2020TrialTD-0903 for ALI Associated With COVID-19

Apr 23, 2020TrialFirst in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19

Jan 13, 2020TrialEffect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of TD-9855

Details

Company Info

Company Overview

—

Mkt Cap

$42.1M

Revenue

$37.8M

Cash

CEODarren Wilbraham

Founded2014

HQSan Francisco, California, United States

ExchangeNYSE/NASDAQ:TBPH

Therapeutic Focus

GastroenterologyCardiovascularMusculoskeletalInfectious DiseaseImmunologyRespiratoryNeurologyOther

Recent SEC Filings

EX-99.1Mar 19, 2026

Theravance Biopharma, Inc. (TBPH) (CIK 0001583107)

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Neurology

Multiple System Atrophy

ampreloxetine

Neurology

Multiple System Atrophy

ampreloxetinePhase 3

Regulatory

Regulatory Timeline

20261 event

SECMar 19

Theravance Biopharma, Inc. (TBPH) (CIK 0001583107)

Accession: 001-36033

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)